Advanced search
Publication Cover
Current Medical Research and Opinion Volume 32, 2016 - Issue 12
Submit an article Journal homepage
515
Views
21
CrossRef citations to date
0
Altmetric
Neurology

Evaluation of the Expanded Disability Status Scale and the Multiple Sclerosis Functional Composite as clinical endpoints in multiple sclerosis clinical trials: quantitative meta-analyses

Aseel Bin SawadMCPHS University, Boston, MA, USA; ;Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0001-6620-0716
ORCID Icon,
Enrique Seoane-VazquezMCPHS University, Boston, MA, USA; Correspondence[email protected]
,
Rosa Rodriguez-MonguioUniversity of Massachusetts Amherst, Amherst, MA, USA;
&
Fatema TurkistaniMCPHS University, Boston, MA, USA; ;Taibah University, Medina, Kingdom of Saudi Arabia
Pages 1969-1974 | Received 02 Apr 2016, Accepted 04 Aug 2016, Published online: 07 Sep 2016

Citations (21)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Marc S. Rendell. (2021) The time to develop treatments for diabetic neuropathy. Expert Opinion on Investigational Drugs 30:2, pages 119-130.
Read now

Articles from other publishers (20)

Peter Alping, Martin Neovius, Fredrik Piehl & Thomas Frisell. (2024) Real‐World Healthcare Cost Savings and Reduced Relapse Rate with Off‐Label Rituximab versus Disease‐Modifying Treatments Approved for Relapsing–Remitting Multiple Sclerosis: A Nationwide Cost‐Effectiveness Study. Annals of Neurology 95:6, pages 1099-1111.
Crossref
Sarah A. Morrow. (2024) Cognitive Impairment in Multiple Sclerosis. Neuroimaging Clinics of North America.
Crossref
A. I. Prokaeva, I. E. Arkhipov, E. E. Dorchinets, D. S. Korobko & N. A. Malkova. (2024) Multiple sclerosis: modern diagnostic markers and prognostic factors of disease progression. Сибирский научный медицинский журнал 44:1, pages 39-51.
Crossref
M. A. Urban, N. V. Komissarova, I. I. Khazieva & I. I. Shamsutdinova. (2023) Predictors of transition from relapsing‑remitting multiple sclerosis to secondary progressive. Medical alphabet:14, pages 40-44.
Crossref
Aleksandra Pogoda-Wesołowska, Angela Dziedzic, Karina Maciak, Adam Stȩpień, Marta Dziaduch & Joanna Saluk. (2023) Neurodegeneration and its potential markers in the diagnosing of secondary progressive multiple sclerosis. A review. Frontiers in Molecular Neuroscience 16.
Crossref
Anabel Granja Domínguez, Raúl Romero Sevilla, Aurora Alemán, Carmen Durán, Anja Hochsprung, Guillermo Navarro, Cristina Páramo, Ana Venegas, Ana Lladonosa & Guillermo Izquierdo Ayuso. (2023) Study for the validation of the FeetMe® integrated sensor insole system compared to GAITRite® system to assess gait characteristics in patients with multiple sclerosis. PLOS ONE 18:2, pages e0272596.
Crossref
Vlad Eugen Tiu, Iulian Enache, Cristina Aura Panea, Cristina Tiu & Bogdan Ovidiu Popescu. (2022) Predictive MRI Biomarkers in MS—A Critical Review. Medicina 58:3, pages 377.
Crossref
Anne Parkinson, Janet Drew, Sally Hall Dykgraaf, Vanessa Fanning, Katrina Chisholm, Mark Elisha, Christian Lueck, Christine Phillips & Jane Desborough. (2021) ‘They're getting a taste of our world’: A qualitative study of people with multiple sclerosis' experiences of accessing health care during the COVID‐19 pandemic in the Australian Capital Territory. Health Expectations 24:5, pages 1607-1617.
Crossref
Olaf Hoffmann & Ralf Gold. (2021) Krankheitsmodifizierende Therapie der sekundär progredienten Multiplen SkleroseDisease-modifying treatment of secondary progressive multiple sclerosis. Der Nervenarzt 92:10, pages 1052-1060.
Crossref
Nik Krajnc, Thomas Berger & Gabriel Bsteh. (2021) Measuring Treatment Response in Progressive Multiple Sclerosis—Considerations for Adapting to an Era of Multiple Treatment Options. Biomolecules 11:9, pages 1342.
Crossref
Nik Krajnc, Gabriel Bsteh & Thomas Berger. (2021) Clinical and Paraclinical Biomarkers and the Hitches to Assess Conversion to Secondary Progressive Multiple Sclerosis: A Systematic Review. Frontiers in Neurology 12.
Crossref
Massimo Filippi, Paolo Preziosa, Dawn Langdon, Hans Lassmann, Friedemann Paul, Àlex Rovira, Menno M. Schoonheim, Alessandra Solari, Bruno Stankoff & Maria A. Rocca. (2020) Identifying Progression in Multiple Sclerosis: New Perspectives. Annals of Neurology 88:3, pages 438-452.
Crossref
Ozbek Damla, Cincin Altug, Kahraman Koytak Pinar, Kepez Alper, Ince Gunal Dilek & Agan Kadriye. (2018) Heart rate variability analysis in patients with multiple sclerosis. Multiple Sclerosis and Related Disorders 24, pages 64-68.
Crossref
Bernard M. J. Uitdehaag. (2018) Disability Outcome Measures in Phase III Clinical Trials in Multiple Sclerosis. CNS Drugs 32:6, pages 543-558.
Crossref
Lucas Immich Gonçalves, Giordani Rodrigues dos Passos, Lucas Piccoli Conzatti, Jorge Luiz Palmeiro Burger, Gustavo Henrique Tomasi, Manuella Édler Zandoná, Luciana Schermann Azambuja, Irênio Gomes, Alexandre Franco, Douglas Kazutoshi Sato & Jefferson Becker. (2018) Correlation between the corpus callosum index and brain atrophy, lesion load, and cognitive dysfunction in multiple sclerosis. Multiple Sclerosis and Related Disorders 20, pages 154-158.
Crossref
Tamara Bushnik. 2018. Encyclopedia of Clinical Neuropsychology. Encyclopedia of Clinical Neuropsychology 1363 1365 .
Tamara Bushnik. 2017. Encyclopedia of Clinical Neuropsychology. Encyclopedia of Clinical Neuropsychology 1 3 .
Gill A. Webster, Dalice A. Sim, Anne C. La Flamme & Nancy E. Mayo. (2017) Evaluation of neurological changes in secondary progressive multiple sclerosis patients treated with immune modulator MIS416: results from a feasibility study. Pilot and Feasibility Studies 3:1.
Crossref
Susan E. Bennett, Lacey E. Bromley, Nadine M. Fisher, Machiko R. Tomita & Paulette Niewczyk. (2017) Validity and Reliability of Four Clinical Gait Measures in Patients with Multiple Sclerosis. International Journal of MS Care 19:5, pages 247-252.
Crossref
Elizabeth A. Mills, Ali Mirza & Yang Mao-Draayer. (2017) Emerging Approaches for Validating and Managing Multiple Sclerosis Relapse. Frontiers in Neurology 8.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.